NCT06742567 Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
| NCT ID | NCT06742567 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | National Institute of Cardiovascular Diseases, Pakistan |
| Condition | Acute Myocardial Infarction of Anterior Wall |
| Study Type | INTERVENTIONAL |
| Enrollment | 472 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2025-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 472 participants in total. It began in 2024-12-02 with a primary completion date of 2025-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18-65 years * Presenting with acute anterior STEMI * Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm * WIHTOUT evidence of LV thrombus. Exclusion Criteria: * Patients with previous anterior myocardial infarction or LAD revascularization procedures * Patients with cardiogenic shock * Patients with LV thrombus * Patients with advanced CKD (Cr \> 2 and those on hemodialysis) * Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000 * History of recent CVA ( within past three months) * Patients with atrial fibrillation or other indications for chronic anticoagulation * Pregnant patients and those with hematological disorders
Contact & Investigator
Abdul Hakeem Professor of Cardiology, Director Cardiac Catheterization Labs, MD FACC FSCAI FASE
PRINCIPAL INVESTIGATOR
NICVD
Frequently Asked Questions
Who can join the NCT06742567 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Acute Myocardial Infarction of Anterior Wall. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06742567 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 472 participants.
Is NCT06742567 currently recruiting?
Yes, NCT06742567 is actively recruiting participants. Contact the research team at ahakeem@gmail.com for enrollment information.
Where is the NCT06742567 trial being conducted?
This trial is being conducted at Karachi, Pakistan.
Who is sponsoring the NCT06742567 clinical trial?
NCT06742567 is sponsored by National Institute of Cardiovascular Diseases, Pakistan. The principal investigator is Abdul Hakeem Professor of Cardiology, Director Cardiac Catheterization Labs, MD FACC FSCAI FASE at NICVD. The trial plans to enroll 472 participants.